INNOVATION
Disease-Modifying Therapies
Donanemab and lecanemab represent a significant breakthrough in Alzheimer’s treatment. Unlike previous medications that only addressed symptoms, these innovative monoclonal antibodies are designed to target and clear amyloid plaques from the brain, potentially slowing the progression of the disease in eligible patients.
Eligibility Criteria
Early-Stage Diagnosis
Eligibility is primarily for individuals with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer’s Disease, where treatment impact is most significant.
Amyloid Confirmation
Patients must have confirmed amyloid plaque deposition in the brain, verified through Amyloid PET scans or cerebrospinal fluid (CSF) testing.
General Health Suitability
Suitability depends on clinical stability, absence of conflicting neurological conditions, and a clear safety profile determined by an MRI brain assessment.
Required Diagnostic Tests
Amyloid PET Scan
The gold standard for confirming the presence of amyloid plaques in the brain. This scan is essential to determine eligibility for plaque-targeting therapies.
Structural MRI Brain Assessment
Required to establish a baseline and rule out other clinical causes. Precision structural mapping ensures the safest possible administration of treatment.
CSF Diagnostics or Blood Biomarkers
Advanced biochemical analysis of cerebrospinal fluid (CSF) or specific blood biomarkers provides definitive confirmation of Alzheimer's pathology.
Safety & Monitoring
Safety is our primary concern. Clinical monitoring protocols include regular MRI surveillance for ARIA (Amyloid-Related Imaging Abnormalities) and routine blood assessments to ensure therapy efficacy and patient wellbeing throughout the treatment journey.
The eSMART Clinic Approach
eSMART Clinics bridge the distance between breakthrough medical research and rural Australian communities. We facilitate the delivery of disease-modifying therapies by integrating our advanced AI diagnostic platform with local medical partners, ensuring patients in regional hubs receive the same high-standard care as those in metropolitan centres.
Our clinics specialise in the logistical coordination required for lecanemab and donanemab treatments. From securing initial PET/MRI imaging in your nearest regional hub to managing the ongoing monitoring protocols, eSMART Clinics provide the clinical framework that makes modern Alzheimer’s care a reality for every Australian family.
